Pharmacy Tirzepatide

About Pharmacy Tirzepatide — Independent Research Digest

What this site is

Pharmacy Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on Tirzepatide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name 'Pharmacy Tirzepatide' reflects an editorial position — a measured, fiduciary reading desk for the tirzepatide trial record, the kind of rigorous data-forward coverage one might expect from a clinical pharmacist reviewing the evidence. The name is not a claim about services offered, regulatory status, or dispensing capability. No prescriptions are written or facilitated here. No products are sold.

Every quantitative claim on this site cites a numbered reference. The Tirzepatide references page carries the full citation list with DOIs and PubMed links. Any claim that cannot be traced to a numbered citation does not appear on this site.

What this site covers

This site covers Tirzepatide — a dual GIP and GLP-1 receptor agonist, FDA-approved for type 2 diabetes (May 2022) and chronic weight management (November 2023) — specifically through the lens of head-to-head trial data versus semaglutide. The primary sources are:

  • SURPASS programme: Phase 3 randomised trials in type 2 diabetes, including SURPASS-2 (the 1,879-patient head-to-head vs semaglutide 1 mg, published in the New England Journal of Medicine, 2021)
  • SURMOUNT programme: Phase 3 randomised trials for obesity and overweight, including SURMOUNT-1 (2,539 patients, 72 weeks), SURMOUNT-5 (the direct 751-patient head-to-head vs semaglutide in obesity), and SURMOUNT-4 (continuation/withdrawal design)
  • The pharmacological characterisation studies (Coskun 2018, Willard 2020)
  • Safety meta-analyses (nine-trial safety analysis, Zeng et al., 2023)
  • Recent 2024–2026 studies including the TriNetX retrospective cohort, the SURPASS-4 two-year post-hoc, and the SURMOUNT-5 quality-of-life analysis

The site does not cover personal dosing advice, prescribing decisions, insurance or access guidance, or vendor sourcing.

Editorial principles

Four rules govern every page on this site:

  1. Numbers first. Every page leads with the most important measured outcome — not an introduction, not a disclaimer, the finding.
  2. Cite everything quantitative. Every dose, percentage, hazard ratio, and p-value maps to a numbered citation with a DOI or PubMed link.
  3. Use only the INN. 'Tirzepatide' — the international non-proprietary name — is the only name used. No brand names appear anywhere on this site.
  4. Acknowledge gaps. Where the evidence is preliminary, sponsor-funded, or mechanistic rather than clinical, the text says so.